No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Diagnostics & Research
ImExHS Limited delivers cloud-powered medical imaging technologies to customers worldwide, including those in Australia. The firm specializes in the development and sale of modular imaging software systems, which encompass comprehensive information management platforms for disciplines such as radiology, cardiology, and pathology, alongside a robust picture archiving and communication system (PACS). Its principal software solutions include AQUILA for radiology, ALULA for pathology, and Antero for cardiology. Moreover, ImExHS offers STELLA.I, a suite of artificial intelligence tools hosted in the cloud, crafted to bolster diagnostic capabilities for medical professionals. The company further extends outsourced radiology and teleradiology services to hospitals and various other healthcare entities. Established in 2001, ImExHS Limited operates from its base in Mascot, Australia.
www.imexhs.comNo one on the platform currently holds IME.AX.
No tracked institution reports a position in IME.AX as of their last filing.
No one on the platform has traded IME.AX yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 9.0% | 21.6% | ||||
| Profit Margin % | -9.9% | -18.8% | -589.3% | |||
| Free Cash Flow Margin % | 0.8% | -13.9% | -484.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $33M | +13.1% | $-0.00 | $-0.00–$-0.00 | — | 1 |
| 2027 | $36M | +8.8% | $0.01 | $0.01–$0.01 | — | 1 |
| 2028 | $39M | +9.2% | $0.01 | $0.01–$0.01 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 5 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-27 | $-0.05 | $0.12 | +340.0% |
| 2026-02-26 | $-0.01 | $-0.01 | +0.0% |
| 2025-09-01 | $-0.03 | $-0.06 | -113.3% |
| 2025-04-30 | $0.02 | $-0.02 | -227.6% |
| 2025-02-27 | $0.02 | $0.02 | +0.0% |
| $4M |
| — |
| ICR.AXIntelicare Holdings Limited | $0.02 | +9.52% | $11M | — |
| MDR.AXMedAdvisor Limited | $0.02 | +0.00% | $14M | — |
Source: Financial Modeling Prep · peers by sector/industry